Israeli drug prevents 100% of COVID patients from deteriorating in trial : vimarsana.com

All 18 hospitalized individuals administered the treatment developed by Israeli biotech company Amorphical in a phase II trial recovered and were discharged in a few days.

Related Keywords

Israel , United States , Brazil , Israeli , Kamal Abu Jabal , Maayan Hayeshua , Nashat Abu Saleh , Yossi Ben , Abu Saleh , Ziv Medical Center , Health Wellness , Samson Assuta Ashdod University Hospital , Nashat Abu , Amorphous Calcium Carbonate ,